Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022
- PMID: 35389977
- PMCID: PMC8989373
- DOI: 10.15585/mmwr.mm7114e1
Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022
Abstract
Cardiac complications, particularly myocarditis and pericarditis, have been associated with SARS-CoV-2 (the virus that causes COVID-19) infection (1-3) and mRNA COVID-19 vaccination (2-5). Multisystem inflammatory syndrome (MIS) is a rare but serious complication of SARS-CoV-2 infection with frequent cardiac involvement (6). Using electronic health record (EHR) data from 40 U.S. health care systems during January 1, 2021-January 31, 2022, investigators calculated incidences of cardiac outcomes (myocarditis; myocarditis or pericarditis; and myocarditis, pericarditis, or MIS) among persons aged ≥5 years who had SARS-CoV-2 infection, stratified by sex (male or female) and age group (5-11, 12-17, 18-29, and ≥30 years). Incidences of myocarditis and myocarditis or pericarditis were calculated after first, second, unspecified, or any (first, second, or unspecified) dose of mRNA COVID-19 (BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]) vaccines, stratified by sex and age group. Risk ratios (RR) were calculated to compare risk for cardiac outcomes after SARS-CoV-2 infection to that after mRNA COVID-19 vaccination. The incidence of cardiac outcomes after mRNA COVID-19 vaccination was highest for males aged 12-17 years after the second vaccine dose; however, within this demographic group, the risk for cardiac outcomes was 1.8-5.6 times as high after SARS-CoV-2 infection than after the second vaccine dose. The risk for cardiac outcomes was likewise significantly higher after SARS-CoV-2 infection than after first, second, or unspecified dose of mRNA COVID-19 vaccination for all other groups by sex and age (RR 2.2-115.2). These findings support continued use of mRNA COVID-19 vaccines among all eligible persons aged ≥5 years.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Jason P. Block, Christopher B. Forrest, Grace M. Lee, and Thomas W. Carton report support from the National Institutes of Health (NIH) as part of the Researching COVID to Enhance Recovery (RECOVER) program. Nidhi Ghildayal reports NIH funding for a postdoctoral position. Michael D. Kappelman reports grants from NIH, PCORI, Helmsley Trust, Abbvie, Arenapharm, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, Eli Lilly, Genentech, Janssen (a subsidiary of Johnson & Johnson, Pfizer, and Takeda) and consulting fees from Abbvie, Janssen, Takeda, and Pfizer; payment for service on a data safety monitoring board for Eli Lilly, and payment for service on the editorial board of the American Journal of Gastroenterology. Kenneth H. Mayer reports grant support from NIH’s COVID-19 Vaccine Trials Network for a Phase III AstraZeneca SARS-CoV-2 vaccine trial. Matthew E. Oster reports institutional support from NIH’s National Heart, Lung, and Blood Institute. No other potential conflicts of interest were disclosed.
Similar articles
-
Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.PLoS Med. 2023 Jun 7;20(6):e1004245. doi: 10.1371/journal.pmed.1004245. eCollection 2023 Jun. PLoS Med. 2023. PMID: 37285378 Free PMC article.
-
Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.PLoS Med. 2022 Jul 28;19(7):e1004056. doi: 10.1371/journal.pmed.1004056. eCollection 2022 Jul. PLoS Med. 2022. PMID: 35900992 Free PMC article.
-
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.BMJ. 2022 Jul 13;378:e069445. doi: 10.1136/bmj-2021-069445. BMJ. 2022. PMID: 35830976 Free PMC article. Review.
-
SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.JAMA Cardiol. 2022 Jun 1;7(6):600-612. doi: 10.1001/jamacardio.2022.0583. JAMA Cardiol. 2022. PMID: 35442390 Free PMC article.
-
Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series.Rev Med Virol. 2022 Jul;32(4):e2318. doi: 10.1002/rmv.2318. Epub 2021 Dec 17. Rev Med Virol. 2022. PMID: 34921468 Review.
Cited by
-
Infectious disease surveillance needs for the United States: lessons from Covid-19.Front Public Health. 2024 Jul 15;12:1408193. doi: 10.3389/fpubh.2024.1408193. eCollection 2024. Front Public Health. 2024. PMID: 39076420 Free PMC article. Review.
-
Public Health Surveillance in Electronic Health Records: Lessons From PCORnet.Prev Chronic Dis. 2024 Jul 11;21:E51. doi: 10.5888/pcd21.230417. Prev Chronic Dis. 2024. PMID: 38991533 Free PMC article.
-
COVID-19 Pandemic- Ethical Challenges for Healthcare Workers Practicing in Resource-Limited Settings.Niger Med J. 2022 Sep 16;63(1):1-9. doi: 10.60787/NMJ-63-1-116. eCollection 2022 Jan-Feb. Niger Med J. 2022. PMID: 38798972 Free PMC article. Review.
-
Post-Acute Cardiovascular Outcomes of COVID-19 in Children and Adolescents: An EHR Cohort Study from the RECOVER Project.medRxiv [Preprint]. 2024 May 15:2024.05.14.24307380. doi: 10.1101/2024.05.14.24307380. medRxiv. 2024. PMID: 38798448 Free PMC article. Preprint.
-
Assessment of Risk for Sudden Cardiac Death Among Adolescents and Young Adults After Receipt of COVID-19 Vaccine - Oregon, June 2021-December 2022.MMWR Morb Mortal Wkly Rep. 2024 Apr 11;73(14):317-320. doi: 10.15585/mmwr.mm7314a5. MMWR Morb Mortal Wkly Rep. 2024. PMID: 38602888 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous